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Abstract
Introduction: Genetic alterations involving the mitogen-activated protein kinase (MAPK) pathway are frequently demonstrated in papil-
lary thyroid cancer (PTC). BRAF(V600E), the most frequent mutation in adult patients, is present in approximately 50% of PTC. Most
clinical studies have demonstrated an association of BRAF(V600E) mutation with aggressive clinicopathological characteristics and high
tumour recurrence, although the results are controversial.
In this study we present the preliminary results of BRAF mutation frequence in a group of 88 Polish patients with papillary thyroid cancer
(PTC) and relate it to the outcome all DTC patients operated in 2004 and 2005. BRAF (V600E) mutation was diagnosed in 38 (43%) of cases.
Material and methods: The presence of BRAF mutation was evaluated in 88 PTC tumours. DNA was isolated from tissue parafin blocks,
and the mutation V600E was evaluated by sequence analysis with an AbiPrism 377 and 3130 xl genetic analyzer (Life Technologies).
Statistical analysis was carried out with the use of SPSS 12 software. The c2 and Kaplan-Meyer survival analysis were performed.
Results: From all analyzed clinico-pathological factors, only older age positively correlated with BRAF mutation frequency (p = 0.0017).
Lymph node/distant metastases, multifocality, and extra-thyroid extension did not correlate with BRAF status. One cancer related death
and two reccurences were observed in the BRAF+ group while one relapse was diagnosed in the BRAF– group.
Conclusions: Although many studies document BRAF mutation as a prognostic factor in PTC our results underline that it is too early to
consider it as a routine clinical predictive factor.
(Pol J Endocrinol 2010; 61 (5): 462–466)
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Streszczenie
Wstęp: Mutacje dotyczące genów na szlaku kinaz MAP (kinazy aktywowane mitogenem)/kinaz ERK (kinazy regulowane sygnałem ze-
wnątrzkomórkowym) są najczęstszymi zdarzeniami molekularnymi w raku brodawkowatym tarczycy (PTC, papillary thyroid cancer). Mutację
genu BRAF (V600E) stwierdza się u około 50% dorosłych chorych z PTC. W większości dotychczas opublikowanych badań występowanie
mutacji BRAF (V600E) wiąże się z agresywnym przebiegiem klinicznym PTC i wysokim odsetkiem nawrotów choroby. Jednak nie wszy-
scy autorzy podzielają tę opinię.
Celem pracy była ocena częstości mutacji BRAF (V600E) i wstępna ocena jej znaczenia predykcyjnego u 88 chorych na raka brodawkowa-
tego tarczycy.
Materiał i metody: Obecność mutacji BRAF (V600E) oceniono w 88 guzach (rakach brodawkowatych). DNA izolowano z bloczków para-
finowych z użyciem sekwencjonatora AbiPrism 377 i 3130xl Genetic Analyzer (Applied Biosystems).W analizie statystycznej wykorzysta-
no: test c2, test U Mann-Whitney oraz ocenę przeżycia metodą Kaplana-Meier.
Wyniki: Mutację BRAF (V600E) stwierdzono u 38 (43%) chorych. Spośród przeanalizowanych czynników kliniczno-patologicznych jedy-
nie starszy wiek korelował z częstością mutacji. Nie wykazano korelacji pomiędzy obecnością mutacji a przerzutami do węzłów chłon-
nych/odległymi, wieloogniskowością czy naciekaniem torebki tarczycy. Stwierdzono jeden zgon i dwa przerzuty raka w grupie BRAF+
i jeden nawrót raka w grupie BRAF–.
Wnioski: Mimo wykazania w wielu pracach mutacji BRAF jako czynnika prognostycznego w PTC wstępne wyniki opisywanego badania
wskazują na potrzebę dalszych badań zanim mutacja BRAF (V600E) stanie się powszechnie stosowanym czynnikiem predykcyjnym
w raku brodawkowatym tarczycy.
(Endokrynol Pol 2010; 61 (5): 462–466)
Słowa kluczowe: rak brodawkowaty tarczycy, mutacja BRAF, znaczenie prognostyczne i predykcyjne
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Introduction
The prognostic impact and predictive value of clinical
and histological features in differentiated thyroid can-
cers (DTC) [1–5], as well as an optimal treatment relat-
ed to disease stage [3, 6–14], are still discussed. Recent
molecular investigations constitute a new approach.
One of the candidates as a predictive marker of PTC
(papillary thyroid cancer) is BRAF mutation, which leads
to constitutive activation of the mitogen-activated pro-
tein kinase (MAPK) pathway. Many papers describing
the relation between the presence of BRAF mutation
and cancer stage, as well as its unfavourable course, have
been published [15–23, for review see 15]. Since BRAF
mutation can be quickly diagnosed preoperatively in
the fine needle aspiration biopsy material, its diagnosis
could be of great value in pre-operative prognostica-
tion of PTC. However, the question arises whether the
predictive potential of BRAF status is sufficient to guide
the extent of surgery.
The aim of this study was a preliminary evaluation
of the frequency of BRAF mutation in our PTC patients
for further investigation of its putative predictive sig-
nificance.
Material and methods
A group of 195 DTC patients primarily operated in the
Clinical Surgery Clinic in Gliwice in 2004–2005 were
assessed for their staging and disease course and relat-
ed to the results of BRAF investigation in paraffin-em-
bedded tumour fragments if available.
The study group consisted of 166 (85%) women and
29 men (15%), mean age 46 years (median 47 years).
Mean time of follow-up was 4 years (median 4 years).
Follicular thyroid cancer (FTC) was diagnosed in 8 (4%)
patients, whereas in the remaining subjects papillary
thyroid cancer (PTC) was diagnosed by postoperative
histopathology.
All patients were treated by total thyroidectomy and
various extents of lymphadenectomy (unilateral modi-
fied cervical lymphadenectomy was performed in 18 cas-
es (20%), bilateral in 4 patients (5%)) and referred for com-
plementary radioiodine therapy. The details of our thy-
roid surgical algorithm are described elsewhere [24].
The presence of BRAF mutation was evaluated in
88 PTC tumours. DNA was isolated from tissue paraf-
fin blocks, and the mutation V600E was evaluated by
sequence analysis with an AbiPrism 377 and 3130 xl
genetic analyzer (Life Technologies).
Statistical analysis was carried out with the use of
SPSS 12 software. The chi2 test, Mann-Whitney U test,
and Kaplan-Meyer survival analysis were performed.
Results
There were 146 (75%) pT1–pT2 patients and 49 (15%)
pT3 subjects in the study group. Lymph node metastas-
es were diagnosed in 57 (29%) cases, whereas distant
metastases were diagnosed in 10 (5%) subjects (Table I).
The 5-year overall and disease-free survival ratios were
98% and 95%, respectively (Fig. 1).
The frequency of BRAF mutation in the analyzed
group of 88 PTCs was 43%. The mean tumour diameter
in the BRAF+ group was 21 mm (the smallest was
8 mm and the largest was 10 cm). In 11% cases the tu-
mour diameter was < 1 cm. Among 50 BRAF negative
(BRAF-) PTCs, mean tumour diameter was 13 mm
(range 4–100 mm). In 30 (60%) cases the tumour was
not greater than 1 cm. Neither the difference in tumour
diameter nor in the frequency of pT1 tumours was sta-
tistically significant.
Analysis of the relationship between mutation, clin-
ical, and pathological risk factors showed a strong asso-
ciation of BRAF mutation with patient age (p = 0.0017).
There was no correlation between other clinical and
pathological risk factors and BRAF presence (Table II).
One cancer-related death and two recurrences were
observed in the BRAF+ group, whereas in the BRAF-
group only 1 relapse was diagnosed. The 5-year dis-
ease-free survival ratio was higher in the BRAF- group
than in the BRAF+ group (98% and 94%, respectively);
however, the difference was statistically insignificant
(Fig. 2).
Table I. Disease stage in 195 studied PTC patients
Tabela I. Stopień zaawansowania choroby w badanej grupie 195 chorych na raka zróżnicowanego tarczycy
T Number of patients Frequency N1 Freguency M1 Freguency
T1 116 60% 22 19% 1 1%
T2 30 15% 8 27% 1 3%
T3 35 18% 18 51% 2 9%
T4 14 7% 9 64% 6 43%
Total 195 100% 57 29% 10 5%
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Discussion
Differentiated thyroid cancers, and papillary and folli-
cular thyroid carcinomas constitute the commonest
endocrine malignancies, which, among other endocrine
neoplasms, are characterized by the most favourable
prognosis. However, about 10% DTC patients die of
cancer and another 7–10% develop local recurrence or
distant metastases [1, 3]. These data have remained
unchanged for years, and the discussion concerning the
optimal treatment strategy is still ongoing [2]. Support-
ers of the radical surgical approach believe that these
operations reduce the risk of cancer recurrence, increase
the effectiveness of radioiodine ablation, enable the use
of thyroglobulin as a sensitive marker of local and dis-
tant metastases, and eliminate the possibility of DTC
conversion to anaplastic thyroid carcinoma [3, 7]. Op-
ponents of this strategy propose operation limited only
to the tumour lobe with isthmus and/or subtotal resec-
Figure 1. Overall and disease-free survival in studied PTC patients
Rycina 1. Prawdopodobieństwo przeżycia całkowitego i bezobjawowego w badanej grupie chorych
Figure 2. Five-year disease-free survival according to BRAF
status: BRAF– 98%, BRAF+ 94% (non significant)
Rycina 2. Prawdopodobieństwo przeżycia bezobjawowego
w zależności od występowania mutacji BRAF. Pięcioletnie
przeżycie bezobjawowe w grupie BRAF– 98% 5-letnie przeżycie
bezobjawowe w grupie BRAF+ 94% (nz)
Table II. Relation between BRAF mutation and clinico-pathological factors
Tabela II. Obecność mutacji BRAF w guzie nowotworowym, a kliniczno-patologiczne czynniki ryzyka
Factor BRAF +38 BRAF –50 p
Women 35 (92%) 42 (84%) ns
Men 3 (8%) 8  (16%)
Mean age at time of surgery (years) 51 42 p = 0.017
Median 55 40
Mean time of follow-up (years) 4 4 ns
Lymph node metastases 13 (34%) 18 (36%) ns
Distant metastases 3 (8%) 1 (2%) ns
Multifocality 11 (29%) 15 (30%) ns
Extrathyroidal infiltration 11 (29%) 13 (26%) ns
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tion of the second lobe in low-risk patients. Moreover,
some of them resign from the complementary radioio-
dine therapy [4, 8]. This conservative approach is relat-
ed to the relatively indolent natural history of PTC and
minimally invasive FTC to the possibility of the use of
radioiodine ablation after less extensive surgery as well
as to the decreased risk of complications.
Similar controversies concern the extent of neck lym-
phadenectomy in PTC [10, 11]. In recent years an in-
creasing number of papers suggesting the safety of rou-
tine central lymph node dissection abandonment in
low-risk patients have been published. The justification
of this approach is connected to the increased probabil-
ity of postoperative complications (higher than previ-
ously reported) and the lack of increased risk of relapse
or cancer-related death, depending on the extent of the
operation [11, 12]. The indications for lateral neck lym-
phadenectomy are also equivocal. Modified selective
lymphadenectomy (after confirmation of metastases)
are carried out most commonly. However, some cen-
tres suggest elective lymphadenectomy [14].
Currently, the most commonly recommended ex-
tent of surgery is total thyroidectomy and resection of
central compartment neck lymph nodes in almost all
patients [15]. Only reliable pre-operative prognostic fac-
tors allowing the selection of DTC cases with favour-
able/unfavourable prognosis would allow appropriate
risk-orientated treatment tailoring. In this setting, one
of the most intensively discussed molecular markers
with both diagnostic and prognostic relevance in PTC
is V600E BRAF mutation, which is present in 30–80% of
papillary cancers (mean: 49% [16]).
Our preliminary data, although based on a relative-
ly small group of 88 PTC patients, fit well into this range.
According to the data published in recent years, the
presence of BRAF mutation is associated with poorer
disease prognosis [15]. A meta-analysis carried out by
Lee et al. [16] including 1168 patients demonstrated the
correlation of BRAF mutation and histological PTC sub-
type, extrathyroidal invasion, and clinical stage of the
disease. However, what is very interesting, the relation-
ship between BRAF mutation and these factors was not
reported in other studies (for review see Handkiewicz
et al. [15]). Age at PTC diagnosis was the most consis-
tent clinical factor associated with BRAF status, accord-
ing to this analysis. This was also confirmed in our study.
The power and significance of an individual risk factor
depended on the type on analysis (uni- or multivari-
ate). In our univariate analysis we did not observe any
correlation between BRAF status and lymph node me-
tastases, but the number of our cases could be insuffi-
cient. While this correlation was reported by many
groups, up to now no study has demonstrated the rela-
tionship between BRAF and the strongest unfavourable
risk factors such as distant metastases [17–23]. Until now
the impact of BRAF status on disease-free survival has
been observed in a few studies only. One of them,
including 102 patients with a median follow-up
> 10 years, reported the association of BRAF mutation
and overall survival [23].
In our dataset, the 5-year disease-free survival was
slightly worse in the BRAF+ group; however, the dif-
ferences between the groups were not significant. The
most important limitation is the rare occurrence of dis-
ease relapse in our group of patients. That is why we
reported not only the BRAF-analyzed subgroup, but the
whole group of patients treated in the years 2004 to 2005.
In the whole 2004–2005 cohort, the 5-year recurrence
rate approached 5%, similarly to our earlier data [25].
Of course, it would be of benefit to have molecular sup-
port for prediction of which patients are at risk of lymph
node metastases. However, the power of this predic-
tion should exceed 90% to be of clinical value.
Summing up the analysis of the impact of BRAF
mutation, it should be emphasized that actual pub-
lished data have demonstrated its significance as
a negative prognostic factor [19–23]. However, from
a clinical point of view, the question of whether this
mutation is a good predictive factor seems to be more
appropriate. It is essential because more aggressive
therapeutic approach — total thyroidectomy with cen-
tral neck dissection followed by radioiodine treatment
— is recommended for BRAF positive patients even if
the tumour diameter is less than 1 cm. Nevertheless,
at this low stage of the disease the prognosis is excel-
lent, and 99% of cases showed no evidence of cancer
recurrence even after incomplete thyroidectomy [25].
In our opinion, taking into consideration BRAF status
only, the risk of inadequate, overly aggressive treat-
ment in low risk DTC patients is high [15]. It is note-
worthy that BRAF mutation may be diagnosed in up
to 60–70% of microcarcinomas [26]. In our data the fre-
quency of BRAF mutation in papillary microcancer is
lower, at about 30% (data not shown).
On the other hand, the opposite question is wheth-
er in BRAF negative patients less extensive surgery is
safe and not related to increased risk of cancer recur-
rence or cancer-related death. Certainly, the answer is
negative in children, in whom the presence of BRAF
mutation is rare [17] and the risk of distant metastases
is high — even 20%. Consequently, it is currently too
early to establish a therapeutic decision on the basis of
BRAF status only. Probably, in order to create a good
prognostic factor in PTC, not a single gene but a group
of genes (gene signature) should be evaluated, and fur-
ther studies are necessary.
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Conclusions
Many studies document that BRAF mutation is a good
prognostic factor in papillary thyroid cancer. However,
our results indicate that it is too early to consider it as
a routine clinical predictive factor.
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